| Ident. | Authors (with country if any) | Title |
|---|
| 000030 (2020) |
Gulzhan Trimova ; Kaoru Yamagata ; Shigeru Iwata ; Shintaro Hirata [Japon] ; Tong Zhang ; Fumi Uemura ; Minoru Satoh [Japon] ; Norma Biln ; Shingo Nakayamada ; Walter P. Maksymowych ; Yoshiya Tanaka | Tumour necrosis factor alpha promotes secretion of 14-3-3η by inducing necroptosis in macrophages |
| 000168 (2020) |
Tsutomu Takeuchi [Japon] ; Yoshiya Tanaka [Japon] ; Sakae Tanaka [Japon] ; Atsushi Kawakami [Japon] ; Yeong-Wook Song [Corée du Sud] ; Yi-Hsing Chen [Taïwan] ; Mitsuhiro Rokuda [Japon] ; Hiroyuki Izutsu [Japon] ; Satoshi Ushijima [Japon] ; Yuichiro Kaneko [Japon] ; Yoshihiro Nakashima [Japon] ; Teruaki Shiomi [Japon] ; Emi Yamada [Japon] | Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan |
| 000190 (2020) |
Yuko Kaneko [Japon] ; Hideto Kameda [Japon] ; Kei Ikeda [Japon] ; Tomonori Ishii [Japon] ; Kosaku Murakami [Japon] ; Hyota Takamatsu [Japon] ; Yoshiya Tanaka [Japon] ; Takayuki Abe [Japon] ; Tsutomu Takeuchi [Japon] | Response to: 'Some concerns from Turkey' by Bilgin et al. |
| 000191 (2020) |
Yoshiya Tanaka [Japon] ; Hideto Kameda [Japon] ; Kazuyoshi Saito [Japon] ; Yuko Kaneko [Japon] ; Eiichi Tanaka [Japon] ; Shinsuke Yasuda [Japon] ; Naoto Tamura [Japon] ; Keishi Fujio [Japon] ; Takao Fujii [Japon] ; Toshihisa Kojima [Japon] ; Tatsuhiko Anzai [Japon] ; Chikuma Hamada [Japon] ; Yoshihisa Fujino [Japon] ; Shinya Matsuda [Japon] ; Hitoshi Kohsaka [Japon] | Response to tocilizumab and work productivity in patients with rheumatoid arthritis: 2-year follow-up of FIRST ACT-SC study. |
| 000298 (2020) |
Yoshikazu Nakaoka ; Mitsuaki Isobe ; Yoshiya Tanaka ; Tomonori Ishii ; Seido Ooka ; Hiroaki Niiro [Japon] ; Naoto Tamura ; Shogo Banno ; Hajime Yoshifuji [Japon] ; Yasushi Sakata ; Atsushi Kawakami ; Tatsuya Atsumi ; Shunsuke Furuta ; Hitoshi Kohsaka ; Katsuya Suzuki ; Ryoki Hara ; Yasuhiro Maejima ; Hiroshi Tsukamoto ; Yoshinari Takasaki ; Katsuhisa Yamashita ; Norihiro Okada ; Shinji Yamakido ; Syuji Takei ; Shumpei Yokota [Japon] ; Norihiro Nishimoto [Japon] | Long-term efficacy and safety of tocilizumab in refractory Takayasu arteritis: final results of the randomized controlled phase 3 TAKT study. |
| 000324 (2020) |
Sae Ochi [Japon] ; Kazuyoshi Saito [Japon] ; Fumitaka Mizoguchi [Japon] ; Shigeaki Kato [Japon] ; Yoshiya Tanaka [Japon] | Insensitivity versus poor response to tumour necrosis factor inhibitors in rheumatoid arthritis: a retrospective cohort study |
| 000502 (2020) |
Kazuhisa Nakano [Japon] ; Kazuyoshi Saito [Japon] ; Aya Nawata [Japon] ; Kentaro Hanami [Japon] ; Satoshi Kubo [Japon] ; Ippei Miyagawa [Japon] ; Yoshihisa Fujino [Japon] ; Shingo Nakayamada [Japon] ; Yoshiya Tanaka [Japon] | Clinical aspects in patients with rheumatoid arthritis complicated with lymphoproliferative disorders without regression after methotrexate withdrawal and treatment for arthritis after regression of lymphoproliferative disorders. |
| 000572 (2020) |
Takahiko Sugihara [Japon] ; Hitoshi Hasegawa ; Haruhito A. Uchida [Japon] ; Hajime Yoshifuji [Japon] ; Yoshiko Watanabe [Japon] ; Eisuke Amiya [Japon] ; Yasuhiro Maejima [Japon] ; Masanori Konishi [Japon] ; Yohko Murakawa [Japon] ; Noriyoshi Ogawa [Japon] ; Shunsuke Furuta [Japon] ; Yasuhiro Katsumata [Japon] ; Yoshinori Komagata [Japon] ; Taio Naniwa [Japon] ; Takahiro Okazaki [Japon] ; Yoshiya Tanaka [Japon] ; Tsutomu Takeuchi [Japon] ; Yoshikazu Nakaoka [Japon] ; Yoshihiro Arimura [Japon] ; Masayoshi Harigai [Japon] ; Mitsuaki Isobe [Japon] | Associated factors of poor treatment outcomes in patients with giant cell arteritis: clinical implication of large vessel lesions |
| 000905 (2019) |
Yuko Kaneko [Japon] ; Hideto Kameda [Japon] ; Kei Ikeda [Japon] ; Tomonori Ishii [Japon] ; Kosaku Murakami [Japon] ; Hyota Takamatsu [Japon] ; Yoshiya Tanaka [Japon] ; Takayuki Abe [Japon] ; Tsutomu Takeuchi [Japon] | Response to: 'Tocilizumab in patients with adult-onset Still's disease refractory to glucocorticoid treatment' by Lee. |
| 000965 (2019) |
Masaru Kato [Japon] ; Yuko Kaneko [Japon] ; Yoshiya Tanaka [Japon] ; Masayuki Inoo [Japon] ; Hitomi Kobayashi-Haraoka [Japon] ; Koichi Amano [Japon] ; Masayuki Miyata [Japon] ; Yohko Murakawa [Japon] ; Hidekata Yasuoka [Japon] ; Shintaro Hirata [Japon] ; Hayato Nagasawa [Japon] ; Eiichi Tanaka [Japon] ; Nobuyuki Miyasaka [Japon] ; Hisashi Yamanaka [Japon] ; Kazuhiko Yamamoto [Japon] ; Isao Yokota [Japon] ; Tatsuya Atsumi [Japon] ; Tsutomu Takeuchi [Japon] | Predictive value of serum amyloid a levels for requirement of concomitant methotrexate in tocilizumab initiation: A post hoc analysis of the SURPRISE study. |
| 000B04 (2019) |
Desirée Van Der Heijde [Pays-Bas, Norvège] ; Michael Schiff [États-Unis] ; Yoshiya Tanaka [Japon] ; Li Xie [États-Unis] ; Gabriella Meszaros [États-Unis] ; Taeko Ishii [États-Unis] ; Marta Casillas [États-Unis] ; Robert A. Ortmann [États-Unis] ; Paul Emery [Royaume-Uni] | Low rates of radiographic progression of structural joint damage over 2 years of baricitinib treatment in patients with rheumatoid arthritis |
| 000B11 (2019) |
Atsushi Ogata [Japon] ; Yoshiya Tanaka [Japon] ; Tomonori Ishii [Japon] ; Motohide Kaneko [Japon] ; Hiroko Miwa [Japon] ; Shino Ohsawa [Japon] ; Reiji Yamakawa [Japon] | Long-term safety and efficacy of weekly subcutaneous tocilizumab monotherapy in patients with rheumatoid arthritis who had an inadequate response to subcutaneous tocilizumab every other week: Results from the open-label extension of the SHINOBI study. |
| 000C71 (2019) |
Yuya Fujita [Japon] ; Masao Nawata [Japon] ; Atsushi Nagayasu [Japon] ; Kazuki Someya [Japon] ; Kazuyoshi Saito [Japon] ; Yoshiya Tanaka [Japon] | Fifty-Two-Week Results of Clinical and Imaging Assessments of a Patient with Rheumatoid Arthritis Complicated by Systemic Sclerosis with Interstitial Pneumonia and Type 1 Diabetes despite Multiple Disease-Modifying Antirheumatic Drug Therapy That Was Successfully Treated with Baricitinib: A Novel Case Report |
| 000D22 (2019) |
Tsutomu Takeuchi [Japon] ; Yoshiya Tanaka [Japon] ; Sakae Tanaka [Japon] ; Atsushi Kawakami [Japon] ; Manabu Iwasaki [Japon] ; Kou Katayama [Japon] ; Mitsuhiro Rokuda [Japon] ; Hiroyuki Izutsu [Japon] ; Satoshi Ushijima [Japon] ; Yuichiro Kaneko [Japon] ; Teruaki Shiomi [Japon] ; Emi Yamada [Japon] ; Désirée Van Der Heijde [Pays-Bas] | Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan |
| 001129 (2018) |
Yuko Kaneko [Japon] ; Hideto Kameda [Japon] ; Kei Ikeda [Japon] ; Tomonoti Ishii [Japon] ; Kosaku Murakami [Japon] ; Hyota Takamatsu [Japon] ; Yoshiya Tanaka [Japon] ; Takayuki Abe [Japon] ; Tsutomu Takeuchi [Japon] | Tocilizumab in patients with adult-onset still's disease refractory to glucocorticoid treatment: a randomised, double-blind, placebo-controlled phase III trial. |
| 001141 (2018) |
Yuko Kaneko [Japon] ; Masaru Kato [Japon] ; Yoshiya Tanaka [Japon] ; Masayuki Inoo [Japon] ; Hitomi Kobayashi-Haraoka [Japon] ; Koichi Amano [Japon] ; Masayuki Miyata [Japon] ; Yohko Murakawa [Japon] ; Hidekara Yasuoka [Japon] ; Shintaro Hirata [Japon] ; Eiichi Tanaka [Japon] ; Nobuyuki Miyasaka [Japon] ; Hisashi Yamanaka [Japon] ; Kazuhiko Yamamoto [Japon] ; Tsutomu Takeuchi [Japon] | Tocilizumab discontinuation after attaining remission in patients with rheumatoid arthritis who were treated with tocilizumab alone or in combination with methotrexate: results from a prospective randomised controlled study (the second year of the SURPRISE study). |
| 001396 (2018) |
Yoshikazu Nakaoka [Japon] ; Mitsuaki Isobe [Japon] ; Syuji Takei [Japon] ; Yoshiya Tanaka [Japon] ; Tomonori Ishii [Japon] ; Shumpei Yokota [Japon] ; Akira Nomura [Japon] ; Seitaro Yoshida [Japon] ; Norihiro Nishimoto [Japon] | Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study). |
| 001404 (2018) |
Yoshiya Tanaka [Japon] ; Hideto Kameda [Japon] ; Kazuyoshi Saito [Japon] ; Yuko Kaneko [Japon] ; Eiichi Tanaka [Japon] ; Shinsuke Yasuda [Japon] ; Naoto Tamura [Japon] ; Keishi Fujio [Japon] ; Takao Fujii [Japon] ; Toshihisa Kojima [Japon] ; Tatsuhiko Anzai [Japon] ; Chikuma Hamada [Japon] ; Yoshihisa Fujino [Japon] ; Shinya Matsuda [Japon] ; Hitoshi Kohsaka [Japon] | Effect of subcutaneous tocilizumab treatment on work/housework status in biologic-naïve rheumatoid arthritis patients using inverse probability of treatment weighting: FIRST ACT-SC study. |
| 001423 (2018) |
Shingo Nakayamada [Japon] ; Satoshi Kubo [Japon] ; Maiko Yoshikawa [Japon] ; Yusuke Miyazaki [Japon] ; Naoki Yunoue [Japon] ; Shigeru Iwata [Japon] ; Ippei Miyagawa [Japon] ; Shintaro Hirata [Japon] ; Kazuhisa Nakano [Japon] ; Kazuyoshi Saito [Japon] ; Yoshiya Tanaka [Japon] | Differential effects of biological DMARDs on peripheral immune cell phenotypes in patients with rheumatoid arthritis. |
| 001511 (2018) |
Atsushi Ogata [Japon] ; Yoshiya Tanaka [Japon] ; Tomonori Ishii [Japon] ; Motohide Kaneko [Japon] ; Hiroko Miwa [Japon] ; Shino Ohsawa [Japon] | A randomized, double-blind, parallel-group, phase III study of shortening the dosing interval of subcutaneous tocilizumab monotherapy in patients with rheumatoid arthritis and an inadequate response to subcutaneous tocilizumab every other week: Results of the 12-week double-blind period. |
| 001758 (2017) |
Stanley B. Cohen [États-Unis] ; Yoshiya Tanaka [Japon] ; Xavier Mariette [France] ; Jeffrey R. Curtis [États-Unis] ; Eun Bong Lee [Corée du Sud] ; Peter Nash [Australie] ; Kevin L. Winthrop [États-Unis] ; Christina Charles-Schoeman [États-Unis] ; Krishan Thirunavukkarasu [Australie] ; Ryan Demasi [États-Unis] ; Jamie Geier [États-Unis] ; Kenneth Kwok [États-Unis] ; Lisy Wang [États-Unis] ; Richard Riese [États-Unis] ; Jürgen Wollenhaupt [Allemagne] | Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials |
